Experts to Gather at Harvard Medical School to Discuss One of the Most Exciting Targets in Cancer Treatment
"HIF-1a: Ready for Prime Time?" symposium to be held on October 22 CAMBRIDGE, Mass., Sept. 23, 2013 /PRNewswire/ -- The role of hypoxia-inducible factor-1a, or HIF-1a, in solid tumor growth has been well characterized. HIF-1a is often present in solid tumors where hypoxic conditions are common, and its presence may be increased by anti-angiogenic medicines and radiation. Because HIF-1a promotes drug resistance, leaders in government, academia, and industry have sought an effective HIF-1a inhibitor for more than a decade. Expert panelists will discuss whether the potential of HIF-1a inhibition is soon to become a reality.
Cancer specialists are invited to a symposium called HIF-1a: Ready for Prime Time? on October 22 at Harvard Medical School. Panelists will discuss emerging evidence that HIF-1a is a master regulator of multiple cancer cell survival mechanisms, the impact of anti-angiogenic agents and radiotherapy on HIF-1a, and strategies to effectively inhibit it.
WHO: Open to academics, health care providers, and pharmaceutical industry professionals interested in the latest research on HIF-1a and the advances that illustrate its value as a therapeutic target
WHAT: HIF-1a: Ready for Prime Time? includes pre-clinical and clinical panels, a keynote presentation, a poster exhibition, and a dinner reception
WHEN: Tuesday, October 22, 2013, from 5:30 p.m. to 9:30 p.m.
WHERE: Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115
REGISTER: Online at www.HIFSymposium.com, via email at firstname.lastname@example.org with "HIF Symposium" in the subject line, or by phone at 845-265-2155 specifying "HIF Symposium"; please note institution, degree, and phone number when registering; there is no fee
The symposium's keynote speaker is Robert A. Weinberg, PhD, Massachusetts Institute of Technology. Confirmed panel participants include: Sarah Conley, PhD, of MedImmune and formerly of the Max Wicha Lab at the University of Michigan; Mark Dewhirst, PhD, of Duke University School of Medicine; Amato Giaccia, PhD, of Stanford University; William Kaelin, MD, of Harvard Medical School; Robert Kerbel, PhD, of the University of Toronto; and Giovanni Melillo, MD, of AstraZeneca and formerly of NCI.
Media Contact: Laura Kempke Schwartz MSL email@example.com +1 781-684-0770
SOURCE Cerulean Pharma Inc.